127 related articles for article (PubMed ID: 37268175)
21. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
22. Research Progress of Axl Inhibitors.
Sun ZG; Liu JH; Zhang JM; Qian Y
Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
[TBL] [Abstract][Full Text] [Related]
23. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
25. Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
Wang C; Jin H; Wang N; Fan S; Wang Y; Zhang Y; Wei L; Tao X; Gu D; Zhao F; Fang J; Yao M; Qin W
Theranostics; 2016; 6(8):1205-19. PubMed ID: 27279912
[TBL] [Abstract][Full Text] [Related]
26. Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance.
Niu ZS; Niu XJ; Wang WH
Future Oncol; 2019 Feb; 15(6):653-662. PubMed ID: 30648886
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer.
Ozyurt R; Ozpolat B
Mol Cancer Ther; 2023 Jul; 22(7):818-832. PubMed ID: 37028809
[TBL] [Abstract][Full Text] [Related]
28. Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation.
Lauter M; Weber A; Torka R
Cell Commun Signal; 2019 Jun; 17(1):59. PubMed ID: 31171001
[TBL] [Abstract][Full Text] [Related]
29. AXL-Driven EMT State as a Targetable Conduit in Cancer.
Antony J; Huang RY
Cancer Res; 2017 Jul; 77(14):3725-3732. PubMed ID: 28667075
[TBL] [Abstract][Full Text] [Related]
30. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target.
Paccez JD; Vasques GJ; Correa RG; Vasconcellos JF; Duncan K; Gu X; Bhasin M; Libermann TA; Zerbini LF
Oncogene; 2013 Feb; 32(6):689-98. PubMed ID: 22410775
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration.
Duijkers FA; Meijerink JP; Pieters R; van Noesel MM
Gene; 2013 May; 521(1):62-8. PubMed ID: 23523856
[TBL] [Abstract][Full Text] [Related]
32. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.
Wang X; Saso H; Iwamoto T; Xia W; Gong Y; Pusztai L; Woodward WA; Reuben JM; Warner SL; Bearss DJ; Hortobagyi GN; Hung MC; Ueno NT
Cancer Res; 2013 Nov; 73(21):6516-25. PubMed ID: 24014597
[TBL] [Abstract][Full Text] [Related]
33. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
Wu F; Li J; Jang C; Wang J; Xiong J
Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
[TBL] [Abstract][Full Text] [Related]
34. Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer.
Song X; Akasaka H; Wang H; Abbasgholizadeh R; Shin JH; Zang F; Chen J; Logsdon CD; Maitra A; Bean AJ; Wang H
J Biol Chem; 2020 Feb; 295(8):2348-2358. PubMed ID: 31959629
[TBL] [Abstract][Full Text] [Related]
35. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
Ishikawa M; Sonobe M; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Date H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S467-76. PubMed ID: 23242819
[TBL] [Abstract][Full Text] [Related]
36. Axl Is a Potential Cancer Prognostic Marker for the Migration and Invasion of Nasopharyngeal Carcinoma.
Jiang C; Zhou L; Wang H; Zhang Q; Xu Y
Adv Clin Exp Med; 2016; 25(3):531-7. PubMed ID: 27629742
[TBL] [Abstract][Full Text] [Related]
37. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
[TBL] [Abstract][Full Text] [Related]
38. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
[TBL] [Abstract][Full Text] [Related]
39. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Scherschinski L; Prem M; Kremenetskaia I; Tinhofer I; Vajkoczy P; Karbe AG; Onken JS
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055167
[TBL] [Abstract][Full Text] [Related]
40. AXL mediates TRAIL resistance in esophageal adenocarcinoma.
Hong J; Belkhiri A
Neoplasia; 2013 Mar; 15(3):296-304. PubMed ID: 23479507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]